Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property c...
Bavarian Nordic A/S (announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency...
The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. Hepatitis D affects nearly 12 million o...
Vaxart, Inc. announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company&r...
SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. SK bioscience, PATH, Slal...
Phase I results provide platform-level validation supporting AdJane's broader development programs in pandemic preparedness, respiratory infectious disea...
Bavarian Nordic A/S announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikung...
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the ...
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are n...
T-CURX leverages Pantherna’s deep expertise and proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovati...
Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has knowhow in vaccine conjugation a...
As healthcare systems around the world grapple with rising costs, growing chronic disease burdens, and increasing demand for innovative therapies, biosimil...
With Proposal #6, AIDS group urges shareholders to vote to request the company produce a report on the impact of extended patent exclusivities on patie...
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...
© 2026 Biopharma Boardroom. All Rights Reserved.
